Peptides for Chronic Inflammation — Evidence Review
"Chronic inflammation" is broad — low-grade systemic inflammation associated with metabolic disease, autoimmune-driven inflammation, post-infectious inflammation, and tissue-specific inflammatory…
"Chronic inflammation" is broad — low-grade systemic inflammation associated with metabolic disease, autoimmune-driven inflammation, post-infectious inflammation, and tissue-specific inflammatory conditions all live under the umbrella. Peptides relevant to one type are not necessarily relevant to others.
This guide focuses on peptides with documented anti-inflammatory mechanisms in published literature — most preclinical, some early human.
Peptides with the strongest anti-inflammatory evidence
KPV (Lysine-Proline-Valine)
Tripeptide fragment of α-MSH. Anti-inflammatory action via melanocortin receptor signaling. Multiple preclinical studies in colitis, IBD, and inflammatory dermatologic models report attenuation of NF-κB and pro-inflammatory cytokine production. Human data is limited; the strongest case is in inflammatory bowel disease research where Phase 1/2 trials are emerging.
KPV is one of the few peptides with reasonably consistent preclinical evidence specifically targeting inflammation rather than the broader "tissue repair" basket.
Thymosin Alpha-1
Naturally occurring peptide with immune-modulating action — increases regulatory T cells and modulates dendritic-cell function. Has Phase 3 data in chronic hepatitis B (where FDA approval exists in some formulations) and septic-shock outcome data in published meta-analyses. Anti-inflammatory mechanism is well-characterized.
Full thymosin alpha-1 profile →
BPC-157 (animal data)
The animal-model literature on BPC-157 includes consistent anti-inflammatory effects in NSAID-enteropathy, ischemia-reperfusion injury, and IBD models. Mechanism includes nitric-oxide system modulation and growth-factor signaling. Zero completed human trials. This is the largest animal-data anti-inflammatory case in the peptide space and the largest gap between animal evidence and human evidence.
LL-37 (Cathelicidin)
Antimicrobial peptide with immune-modulating action. Plays roles in both inflammation initiation (recruiting immune cells to infection sites) and resolution. Therapeutic applications are still being characterized; the inflammation profile is dose- and context-dependent.
Supporting cast
TB-500
Anti-inflammatory effects in tissue-injury contexts in animal models. Less inflammation-specific than KPV or thymosin alpha-1; the evidence is more about tissue repair where inflammation is one component.
What the evidence does not support
- Peptides as substitutes for established anti-inflammatory therapy (NSAIDs, corticosteroids, biologics) in active inflammatory disease
- Claims that any peptide "resets the immune system"
- Use to lower CRP without an underlying cause being identified
Where to source
- BPC-157 vendor rankings — 12 vendors ranked
- TB-500 vendor rankings — limited; data still aggregating
KPV and thymosin alpha-1 vendor data is sparse — the compounds are less commonly tested by independent programs.
What we don't know
- Whether anti-inflammatory peptides modify long-term outcomes in chronic inflammatory conditions
- Comparative efficacy across the class — no head-to-head trials exist
- Optimal dosing and duration in any specific inflammatory disease
- Interaction effects with conventional anti-inflammatory medications
Methodology
Read the full methodology.
This page is educational. Chronic inflammation as a complaint typically reflects a specific underlying condition that should be diagnosed and treated as such, not approached generically.